Biocept (BIOC) Stock Climbs On CFS Testing Availability

Biocept BIOC Stock News

Biocept Inc (NASDAQ: BIOC) is making a run for the top in the market this morning, trading on gains of around 15%. The gains come after the company announced the validation and availability of a new liquid biopsy. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BIOC Stock Pops On CFS Testing Availability

In a press release issued early this morning, Biocept announced that a new product has been validated and is now available. The product is a new line of Target Selector assays that allow phsicians to evaluate the cerbrospinal fluid of their patients.

The test was designed to locate circulating tumor cells and biomarkers for patients with breast and lung cancer that are suspected to have central nervous system metastases.

In the release, BIOC said that the presence of circulating tumor cells in CFS may be an indicator of brain metastases. Unfortunately around 30% of patients with breast cancer and 36% of patients with lung cancer will develop brain metastases. Of course, the ability to detect these metastases earlier could lead to better outcomes for patients.

In a statement, Michael W. Nall, President and CEO at BIOC, had the following to offer:

We are very pleased to make our Target Selectorâ„¢ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer. Among the significant capabilities of our technology is its versatility, which enables applications in a variety of clinical situations and for use with multiple types of biofluids.

Why This News Is So Important

At the end of the day, any time a biotech company brings a new product to the market, it’s an exciting bit of news. After all, new products in the space have the potential to generate meaningful revenue. So, it’s not surprising to see that Biocept investors are excited.

However, there’s more to the news than meets the eye.

At the moment, imaging tools like MRIs are used to help diagnose brain metastases. However, these tools are unreliable. Often times, these tests lead to false negatives, leading to progression and in many cases, death.

However, BIOC now has a way to detect circulating tumor cells in CFS. This will provide a more precise diagnostic tool for doctors, helping to ensure that false negatives are kept at a minimum and helping patients receive the treatments they need when they need them.

All in all, this assay is likely going to prove to be a very important one for BIOC in terms of revenue as it is likely the most accurate way to detect brain metastases in this patient population.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.